Adjuvant effect of cationic liposomes for subunit influenza vaccine: Influence of antigen loading method, cholesterol and immune modulators

Pharmaceutics

Volumn 5, Issue 3, 2013, Pages 392-410

  Barnier Quer, Christophe ^a,c   Elsharkawy, Abdelrahman ^a   Romeijn, Stefan ^a   Kros, Alexander ^b   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adjuvant; Cationic liposomes; Cholesterol; CpG; H3N2; Hemagglutinin; Imiquimod; Immunogenicity; Influenza

Indexed keywords

CHOLESTEROL; HEMAGGLUTININ; INFLUENZA VACCINE; LIPOSOME;

ADJUVANT THERAPY; ADSORPTION KINETICS; ANIMAL CELL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLUENZA; INFLUENZA VACCINATION; LIPID BILAYER; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; UPREGULATION; VACCINE PRODUCTION; ZETA POTENTIAL;

EID: 84880839905     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics5030392     Document Type: Article

References (48)

1. Parodi, V.; de Florentiis, D.; Martini, M.; Ansaldi, F. Inactivated influenza vaccines: Recent progress and implications for the elderly. Drugs Aging 2011, 28, 93-106.
2. Perrie, Y.; Mohammed, A.R.; Kirby, D.J.; McNeil, S.E.; Bramwell, V.W. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 2008, 364, 272-280.
3. Korsholm, K.S.; Andersen, P.L.; Christensen, D. Cationic liposomal vaccine adjuvants in animal challenge models: Overview and current clinical status. Expert Rev. Vaccines 2012, 11, 561-577.
4. Watson, D.S.; Endsley, A.N.; Huang, L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30, 2256-2272.
5. Perrie, Y.; Kastner, E.; Kaur, R.; Wilkinson, A.; Ingham, A.J. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum. Vaccin. Immunother. 2013, 9, doi:10.4161/hv.24694.
6. Schwendener, R.A.; Lagocki, P.A.; Rahman, Y.E. The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim. Biophys. Acta 1984, 772, 93-101.
7. Miller, C.R.; Bondurant, B.; McLean, S.D.; McGovern, K.A.; O'Brien, D.F. Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998, 37, 12875-12883.
8. Barnier-Quer, C.; Elsharkawy, A.; Romeijn, S.; Kros, A.; Jiskoot, W. Cationic liposomes as adjuvants for influenza hemagglutinin: More than charge alone. Eur. J. Pharm. Biopharm. 2012, 81, 294-302.
9. Bal, S.M.; Hortensius, S.; Ding, Z.; Jiskoot, W.; Bouwstra, J.A. Co-encapsulation of antigen and toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 2011, 29, 1045-1052.
10. Alving, C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140, 1-13.
11. Amorij, J.P.; Kersten, G.F.; Saluja, V.; Tonnis, W.F.; Hinrichs, W.L.; Slütter, B.; Bal, S.M.; Bouwstra, J.A.; Huckriede, A.; Jiskoot, W. Towards tailored vaccine delivery: Needs, challenges and perspectives. J. Control. Release 2012, 161, 363-376.
12. O'Hagan, D.T.; de Gregorio, E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 2009, 14, 541-551.
13. Wilson, K.D.; de Jong, S.D.; Tam, Y.K. Lipid-based delivery of cpg oligonucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61, 233-242.
14. Rizwan, S.B.; McBurney, W.T.; Young, K.; Hanley, T.; Boyd, B.J.; Rades, T.; Hook, S. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid a stimulate robust cellular and humoral immune responses. J. Control. Release 2013, 165, 16-21.
15. Suzuki, H.; Wang, B.; Shivji, G.M.; Toto, P.; Amerio, P.; Tomai, M.A.; Miller, R.L.; Sauder, D.N. Imiquimod, a topical immune response modifier, induces migration of langerhans cells. J. Invest. Dermatol. 2000, 114, 135-141.
16. Babai, I.; Samira, S.; Barenholz, Y.; Zakay-Rones, Z.; Kedar, E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and il-2 or gm-csf. II. Induction of th1 and th2 responses in mice. Vaccine 1999, 17, 1239-1250.
17. Martin, R.M.; Brady, J.L.; Lew, A.M. The need for igg2c specific antiserum when isotyping antibodies from c57bl/6 and nod mice. J. Immunol. Methods 1998, 212, 187-192.
18. Copland, M.J.; Baird, M.A.; Rades, T.; McKenzie, J.L.; Becker, B.; Reck, F.; Tyler, P.C.; Davies, N.M. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003, 21, 883-890.
19. Hartmann, G.; Weiner, G.J.; Krieg, A.M. Cpg DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 1999, 96, 9305-9310.
20. Larange, A.; Antonios, D.; Pallardy, M.; Kerdine-Romer, S. Tlr7 and Tlr8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 2009, 85, 673-683.
21. Jeras, M.; Bergant, M.; Repnik, U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl. Immunol. 2005, 14, 231-244.
22. Lindblad, E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004, 82, 497-505.
23. Huckriede, A.; Bungener, L.; ter Veer, W.; Holtrop, M.; Daemen, T.; Palache, A.M.; Wilschut, J. Influenza virosomes: Combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003, 21, 925-931.
24. Vannier, W.E.; Snyder, S.L. Antibody responses to liposome-associated antigen. Immunol. Lett. 1988, 19, 59-64.
25. Therien, H.M.; Lair, D.; Shahum, E. Liposomal vaccine: Influence of antigen association on the kinetics of the humoral response. Vaccine 1990, 8, 558-562.
26. Tan, L.; Weissig, V.; Gregoriadis, G. Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes. Asian Pac. J. Allergy Immunol. 1991, 9, 25-30.
27. White, W.I.; Cassatt, D.R.; Madsen, J.; Burke, S.J.; Woods, R.M.; Wassef, N.M.; Alving, C.R.; Koenig, S. Antibody and cytotoxic t-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 1995, 13, 1111-1122.
28. Serre, K.; Machy, P.; Grivel, J.C.; Jolly, G.; Brun, N.; Barbet, J.; Leserman, L. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface ig of antigen-specific b cells. J. Immunol. 1998, 161, 6059-6067.
29. Batista, F.D.; Harwood, N.E. The who, how and where of antigen presentation to b cells. Nat. Rev. Immunol. 2009, 9, 15-27.
30. Foged, C.; Arigita, C.; Sundblad, A.; Jiskoot, W.; Storm, G.; Frokjaer, S. Interaction of dendritic cells with antigen-containing liposomes: Effect of bilayer composition. Vaccine 2004, 22, 1903-1913.
31. Bakouche, O.; Gerlier, D. Enhancement of immunogenicity of tumour virus antigen by liposomes: The effect of lipid composition. Immunology 1986, 58, 507-513.
32. Batenjany, M.M.; Boni, L.T.; Guo, Y.; Neville, M.E.; Bansal, S.; Robb, R.J.; Popescu, M.C. The effect of cholesterol in a liposomal muc1 vaccine. Biochim. Biophys. Acta 2001, 1514, 280-290.
33. Ishida, T.; Yasukawa, K.; Kojima, H.; Harashima, H.; Kiwada, H. Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes. Int. J. Pharm. 2001, 224, 69-79.
34. Finkelman, F.D.; Holmes, J.; Katona, I.M.; Urban, J.F., Jr.; Beckmann, M.P.; Park, L.S.; Schooley, K.A.; Coffman, R.L.; Mosmann, T.R.; Paul, W.E. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990, 8, 303-333.
35. Veit, M.; Thaa, B. Association of influenza virus proteins with membrane rafts. Adv. Virol. 2011, 2011, doi:10.1155/2011/370606.
36. Amacker, M.; Engler, O.; Kammer, A.R.; Vadrucci, S.; Oberholzer, D.; Cerny, A.; Zurbriggen, R. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic t cells. Int. Immunol. 2005, 17, 695-704.
37. Christensen, D.; Henriksen-Lacey, M.; Kamath, A.T.; Lindenstrom, T.; Korsholm, K.S.; Christensen, J.P.; Rochat, A.F.; Lambert, P.H.; Andersen, P.; Siegrist, C.A, et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct cd4 t cell-inducing capacity compared to its unsaturated analog. J. Control. Release 2012, 160, 468-476.
38. Lambrecht, B.N.; Kool, M.; Willart, M.A.; Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 2009, 21, 23-29.
39. Martinon, F.; Mayor, A.; Tschopp, J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 2009, 27, 229-265.
40. Bal, S.M.; Slütter, B.; Verheul, R.; Bouwstra, J.A.; Jiskoot, W. Adjuvanted, antigen loaded n-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 2012, 45, 475-481.
41. Nembrini, C.; Stano, A.; Dane, K.Y.; Ballester, M.; van der Vlies, A.J.; Marsland, B.J.; Swartz, M.A.; Hubbell, J.A. Nanoparticle conjugation of antigen enhances cytotoxic t-cell responses in pulmonary vaccination. Proc. Natl. Acad. Sci. USA 2011, 108, E989-E997.
42. Joseph, A.; Louria-Hayon, I.; Plis-Finarov, A.; Zeira, E.; Zakay-Rones, Z.; Raz, E.; Hayashi, T.; Takabayashi, K.; Barenholz, Y.; Kedar, E. Liposomal immunostimulatory DNA sequence (iss-odn): An efficient parenteral and mucosal adjuvant for influenza and hepatitis b vaccines. Vaccine 2002, 20, 3342-3354.
43. Geeraedts, F.; Goutagny, N.; Hornung, V.; Severa, M.; de Haan, A.; Pool, J.; Wilschut, J.; Fitzgerald, K.A.; Huckriede, A. Superior immunogenicity of inactivated whole virus h5n1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS Pathog. 2008, 4, e1000138.
44. Weldon, W.C.; Zarnitsyn, V.G.; Esser, E.S.; Taherbhai, M.T.; Koutsonanos, D.G.; Vassilieva, E.V.; Skountzou, I.; Prausnitz, M.R.; Compans, R.W. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 2012, 7, e41501.
45. Slütter, B.; Bal, S.M.; Ding, Z.; Jiskoot, W.; Bouwstra, J.A. Adjuvant effect of cationic liposomes and cpg depends on administration route. J. Control. Release 2011, 154, 123-130.
46. Chollet, J.L.; Jozwiakowski, M.J.; Phares, K.R.; Reiter, M.J.; Roddy, P.J.; Schultz, H.J.; Ta, Q.V.; Tomai, M.A. Development of a topically active imiquimod formulation. Pharm. Dev. Technol. 1999, 4, 35-43.
47. O'Neill, E.; Krauss, S.L.; Riberdy, J.M.; Webster, R.G.; Woodland, D.L. Heterologous protection against lethal a/hongkong/156/97 (h5n1) influenza virus infection in c57bl/6 mice. J. Gen. Virol. 2000, 81, 2689-2696.
48. Droebner, K.; Haasbach, E.; Fuchs, C.; Weinzierl, A.O.; Stevanovic, S.; Buttner, M.; Planz, O. Antibodies and cd4(+) t-cells mediate cross-protection against h5n1 influenza virus infection in mice after vaccination with a low pathogenic h5n2 strain. Vaccine 2008, 26, 6965-6974.